Seres Therapeutics Shares Owned By Institutions vs. Operating Margin
| 1S9 Stock | EUR 0.84 0.01 1.20% |
For Seres Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Seres Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Seres Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Seres Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Seres Therapeutics over time as well as its relative position and ranking within its peers.
Seres |
Seres Therapeutics Operating Margin vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Seres Therapeutics's current stock value. Our valuation model uses many indicators to compare Seres Therapeutics value to that of its competitors to determine the firm's financial worth. Seres Therapeutics is number one stock in shares owned by institutions category among its peers. It also is number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Seres Therapeutics' earnings, one of the primary drivers of an investment's value.Seres Operating Margin vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Seres Therapeutics |
| = | 85.90 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Seres Therapeutics |
| = | (17.02) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Seres Operating Margin Comparison
Seres Therapeutics is currently under evaluation in operating margin category among its peers.
Seres Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Seres Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Seres Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Seres Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Seres Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. SERES THERAPEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 155 people.
Seres Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Seres Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Seres Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Seres Therapeutics' important profitability drivers and their relationship over time.
Use Seres Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Seres Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Seres Therapeutics will appreciate offsetting losses from the drop in the long position's value.Seres Therapeutics Pair Trading
Seres Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Seres Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Seres Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Seres Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Seres Therapeutics to buy it.
The correlation of Seres Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Seres Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Seres Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Seres Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Seres Therapeutics position
In addition to having Seres Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Basic Utilities Thematic Idea Now
Basic Utilities
Companies involved in production and distribution of electric, gas, water, and other energy utilities. The Basic Utilities theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Basic Utilities Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Trending Equities. For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
To fully project Seres Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Seres Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Seres Therapeutics' income statement, its balance sheet, and the statement of cash flows.